Lilly Offers up to $1B for Alzheimer's Drug; Bial Cuts Failed Parkinson's Drug

AlzeCure shares soar over 300% after Eli Lilly strikes Alzheimer’s deal worth over $1bn - European Biotechnology Magazine

Swedish biotech AlzeCure Pharma entered a collaboration and licensing agreement with Eli Lilly, granting the biopharma giant global rights to its Alzheimer’s disease candidate Alzstatin (ACD680). Under the terms of the deal, Alzecure will receive $10 million upfront and could receive more than $1 billion in development and commercial milestone payments, in addition to tiered royalties on future sales. The post AlzeCure shares soar over 300% afte…

Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug

Plus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker will pay $10 million upfront and potentially more than $1 billion ...

Alzecure enters collaboration and with Lilly for Alzheimer’s project

Partnership grants Lilly global rights to Alzstatin ACD680